<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs001200.v1.p1" parentStudy="phs001200.v1.p1" createDate="2016-08-26" modDate="2017-02-21">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigators</td><td>Ruth R Montgomery, PhD</td><td>Yale University, New Haven, CT, USA</td></tr>
		<tr><td>Principal Investigators</td><td>Steven H Kleinstein, PhD</td><td>Yale University, New Haven, CT, USA</td></tr>
		<tr><td>Principal Investigators</td><td>J. Christopher Love, PhD</td><td>Massachusetts Institute of       Technology, Cambridge, MA, USA</td></tr>
		<tr><td>Funding Source</td><td>U19AI089992</td><td>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA</td></tr>
		<tr><td>Funding Source</td><td>U19AI089859</td><td>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Neutralizing Antibodies against West Nile Virus from Human B Cells</StudyNameEntrez>
	<StudyNameReportPage>Neutralizing Antibodies against West Nile Virus Identified Directly from Human B Cells by Single-Cell Analysis and Next Generation Sequencing</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case Set</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>West Nile virus (WNV) infection is a mosquito-borne disease that can cause severe neurological illness. We analyzed the humoral response to WNV of subjects infected with WNV at different stages of the infection and at different levels of detail, from single cells to the repertoire level. We integrated single-cell analysis by microengraving with next-generation sequencing and identified four novel WNV neutralizing antibodies with potential use as therapeutics against WNV infection. The results indicate persistence of WNV-specific memory B cells and antibody-secreting cells in post-convalescent subjects and suggest that the antibody response itself does not predict the clinical severity of the disease. </p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>Confirmation of West Nile Virus infection<br/> Diagnosis and stratification of WNV infection were determined following CDC guidelines and definitions to a severe neuroinvasive phenotype, mild fever-only phenotype, or asymptomatic infection. Infection was validated by qualitative rapid nucleic acid test at the blood bank, positive immunoblot or IgM ELISAs. </p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="26481611"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="West Nile Fever"/>
		<Disease vocab_source="MESH" vocab_term="West Nile virus"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigators">
			<AttName>Ruth R Montgomery, PhD</AttName>
			<Institution>Yale University, New Haven, CT, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Steven H Kleinstein, PhD</AttName>
			<Institution>Yale University, New Haven, CT, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>J. Christopher Love, PhD</AttName>
			<Institution>Massachusetts Institute of       Technology, Cambridge, MA, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>U19AI089992</AttName>
			<Institution>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>U19AI089859</AttName>
			<Institution>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="3" shortName="DS-IR-IRB" longName="Disease-Specific (Immunological Research, IRB)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NIAID</DacName>
      <DacFullName>NIAID DAC</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs001200.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>yes</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001200.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001200.v1.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="3">
        <ConsentName>Disease-Specific (Immunological Research, IRB)</ConsentName>
        <ConsentAbbrev>DS-IR-IRB</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Immunological Research.
Requestor must provide documentation of local IRB approval.</UseLimitation>
        <IrbRequired>Yes</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
